Related Experiment Videos
Stable plasma concentrations of unbound ropivacaine during postoperative epidural infusion for 24-72 hours in
C B Berde1, M Yaster, O Meretoja
1Children's Hospital, Boston, MA, USA.
Insights
Continuous epidural ropivacaine infusion in children aged 1-9 years demonstrated stable unbound plasma concentrations over 24-72 hours, with no age-related differences and no observed toxicity.
Area of Science:
- Pediatric Anesthesiology
- Pharmacokinetics
- Pain Management
Background:
- Continuous epidural ropivacaine infusion is used for pediatric analgesia.
- Limited data exists on long-term pharmacokinetic profiles in children.
Purpose of the Study:
- To evaluate the pharmacokinetics and safety of a 24-72 hour continuous epidural ropivacaine infusion in children aged 1-9 years.
- To assess plasma concentrations and potential toxicity.
Main Methods:
- An open, multi-center study involving 29 pediatric patients (1-9 years) undergoing major surgery.
- Lumbar epidural catheters were placed, followed by a ropivacaine bolus and a continuous infusion (0.4 mg kg(-1) h(-1)) for 24-72 hours.
Main Results:
- Total ropivacaine plasma concentrations increased over time, while unbound concentrations remained stable and below adult toxicity thresholds.
- No age-dependency was observed in apparent unbound clearance.
- No systemic toxicity or cardiovascular effects were noted; additional analgesics were administered.
Conclusions:
- Continuous epidural ropivacaine infusion at 0.4 mg kg(-1) h(-1) for 24-72 hours is safe and effective in children aged 1-9 years.
- Stable unbound plasma concentrations suggest predictable pharmacokinetics without age-related variations.
Background And Objectives:
The aim of this open, non-controlled, multi-centre study was to evaluate the pharmacokinetics and safety of a 24-72 h continuous epidural ropivacaine infusion in children aged 1-9 yr.
Methods:
After induction of general anaesthesia, 29 ASA I-II children, scheduled for major surgery in dermatomes below T10 had lumbar epidural catheters placed. A bolus of ropivacaine, 2 mg kg(-1), was given over 4 min, followed immediately by an infusion of 2 mg mL(-1) ropivacaine 0.4 mg kg(-1) h(-1) for the next 24-72 h.
Results:
Plasma concentrations of total ropivacaine (mean 0.83 and 1.06 mg L(-1) at 16-31 and 59-72 h, respectively) and alpha1-acid-glucoprotein (mean 13 and 25 micromol L(-1) at baseline and 59-72 h) increased over the course of the infusion. Plasma concentrations of unbound ropivacaine were stable throughout the epidural infusion (mean 0.021 range 0.011-0.068 and mean 0.016 range 0.009-0.023 mg L(-1) at 16-31 and 59-72 h, respectively) and were well below threshold levels associated with central nervous system toxicity in adults (0.35 mg L(-1)). Apparent unbound clearance (mean 346, range 86-555 mL min(-1) kg(-1)) showed no age-dependency. No signs of systemic toxicity or cardiovascular effects were observed. All patients received additional analgesics with morphine.
Conclusion:
Following a 24-72 h epidural infusion of ropivacaine 0.4 mg kg(-1) h(-1) in 1-9-yr-old children, the plasma concentrations of unbound ropivacaine were stable over time with no age-dependency.
Related Concept Videos
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Local Anesthetics: Clinical Application as Spinal Anesthesia
Parenteral Anesthetics: Overview
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children